222.15
+4.77(+2.19%)
Currency In USD
| Previous Close | 217.38 |
| Open | 217.73 |
| Day High | 223.24 |
| Day Low | 212.7 |
| 52-Week High | 242 |
| 52-Week Low | 118.03 |
| Volume | 602,412 |
| Average Volume | 699,972 |
| Market Cap | 13.57B |
| PE | -48.29 |
| EPS | -4.6 |
| Moving Average 50 Days | 213.31 |
| Moving Average 200 Days | 192.33 |
| Change | 4.77 |
If you invested $1000 in Ascendis Pharma A/S (ASND) 10 years ago, it would be worth $12,185.96 as of February 08, 2026 at a share price of $222.15. Whereas If you bought $1000 worth of Ascendis Pharma A/S (ASND) shares 5 years ago, it would be worth $1,443.19 as of February 08, 2026 at a share price of $222.15.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026
GlobeNewswire Inc.
Feb 04, 2026 9:01 PM GMT
COPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report full year 2025 financial results and provide a business update on Wednesday, February 11, 2026, after the close of the U.S.
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 09, 2026 11:01 PM GMT
- Rapidly transforming into a leading global biopharma companyCOPENHAGEN, Denmark, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2026 key corporate mil
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)
GlobeNewswire Inc.
Jan 08, 2026 9:01 PM GMT
– Once-weekly TransCon® CNP and TransCon® hGH combination therapy showed durable growth without compromising safety or tolerability at 52 weeks – Annualized growth velocity (AGV) exceeded the 97th-percentile of average stature children – ACH height